Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China
Long-term TAF treatment demonstrated durable virologic efficacy, sustained biochemical and serological responses, and favorable renal and bone safety over eight years in Chinese participants with chronic hepatitis B.
Authors
- Tahmineh Yazdi
- Leland J. Yee (ORCID: https://orcid.org/0000-0002-0369-5878)
- ChengWei Chen
- Irina Botros
- Li Z (ORCID: https://orcid.org/0000-0002-6141-5184)
- Yanwen Luo
- Lunli Zhang
- Guozhong Gong
- Zhongping Duan
- Qing Xie
- Roberto Mateo
- Shanming Wu
- Yan Chen
- Jun Li
- Yongfeng Yang
- Qin Ning
- Yan Huang
- Hong Tang
- Mingxiang Zhang
- Feng Lin
- Jidong Jia
- Frida Abramov
- Jinlin Hou
- Yu Chen
Institutions
- Central South University (CN)
- Nanchang University (CN)
- Shanghai Jiao Tong University (CN)
- Capital Medical University (CN)
- Sichuan University (CN)
- Ruijin Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Nanfang Hospital (CN)
- Unilever (China) (CN)
- Shanghai Public Health Clinical Center (CN)
- 81th Hospital of PLA (CN)
- Hainan General Hospital (CN)
- Gilead Sciences (United States) (US)
- Beijing YouAn Hospital (CN)
- Beijing Friendship Hospital (CN)
- Nanjing Second Hospital (CN)
- Jiangsu Province Hospital (CN)
- People's Liberation Army 411 Hospital (CN)
- The Sixth People's Hospital of Shenyang (CN)
- Xiangya Hospital Central South University (CN)
- Tongji Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Clinical and Translational Hepatology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.14218/jcth.2025.00438
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences